Oncotelic Therapeutics, Inc. announced the beta launch of a proprietary SEC chatbot, utilizing DAO token (PDAO) and Artificial Intelligence (AI). This chatbot allows users to receive conversational responses about the Company's SEC filings filed as of April 12, 2023. Only holders of the Pet2DAO token, PDAO, can access the chatbot.

Users can compare its SEC chatbot with traditional ChatGPT. This beta version aims to improve with inputs.